R&D Pipeline
Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.
Our research focuses on developing a broad portfolio of drug candidates across areas of significant unmet needs. The programs in our portfolio are derived from our profound scientific and clinical expertise and are currently at various stages of preclinical and clinical developments. We are committed to advancing our programs and expanding our portfolio with an end goal of potentially providing therapies to patients in need.
Oncology
HPK1
Oncology
GCN2
Oncology
Neurodegenerative Diseases
c-Abl
ALS, Parkinson’s
c-Abl/PET
PET tracer for c-Abl therapeutic
LRRK2/c-Abl
Parkinson’s
1STBIO-LigaChemBio Joint Pipeline
Undisclosed
Oncology
Undisclosed
Oncology
Platform Technology
1ST-501
AI Drug Discovery Engine
1ST-FINDERTM
TPD